FDA Approves DATROWAY® for Advanced HR+/HER2- Breast Cancer
Trop-2-directed antibody-drug conjugateA new breast cancer treatment option
The United States Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) on January 17, 2025, for adults with hormone receptor-positive (HR+), HER2-negative breast cancer that is unresectable or metastatic and has already been treated with both endocrine therapy and chemotherapy.
What is DATROWAY?
DATROWAY is a Trop-2-directed antibody-drug conjugate that delivers a chemotherapy payload directly to cancer cells. It was developed by Daiichi Sankyo, Inc.
Administration
DATROWAY is administered via IV infusion once every 3 weeks.
Clinical Trial Snapshot
- Trial Name: TROPION-Breast01
- Patients: 732 (across 20 countries; 59 from the U.S.)
- Design: Compared DATROWAY vs. chemotherapy
- Key Results:
- Progression-Free Survival (PFS):
- DATROWAY: 6.9 months
- Chemotherapy: 4.9 months
- Also showed improved response rates and duration of response.
Potential Side Effects
DATROWAY may cause:
- Severe lung problems, including life-threatening or fatal interstitial lung disease (ILD)
- Mouth sores, eye irritation, keratitis
- Risk to unborn babies
Most common side effects include:
- Mouth ulcers, nausea, fatigue
- Low white/red blood cell counts, hair loss
- Constipation, dry eyes, liver enzyme elevation
Summary
DATROWAY offers a new treatment option for patients with difficult-to-treat HR+/HER2- breast cancer, showing better cancer control than standard chemo — but it carries significant risks that must be carefully managed.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
When Political Priorities and FDA Science Collide
HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...
What to Know about FDA’s Revised Peptide Guidance
What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...